Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 28, 2026Clinical Case ReportsOpen Access

Belumosudil for Long‐Standing Refractory Chronic Graft‐Versus‐Host Disease: A Two‐Patient Case Report

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMihee KimHJHo Cheol JangGSGa‐Young Song

Discussion

Loading...

Member takes

Overview

Case report shows improvement in symptoms of chronic GVHD, suggesting possible extended use.

Key Points

  • This report aims to explore the effects of belumosudil on refractory chronic graft-versus-host disease (GVHD) over a long duration.
  • Two patients with long-standing fibrotic chronic GVHD treated with belumosudil.
  • Monitoring of patient-reported outcomes and infection-related hospitalizations.
  • Evaluated NIH organ scores over time.
  • Clinically meaningful improvements reported by both patients.
  • Reduced hospitalizations related to infections.
  • NIH organ scores remained stable while patients experienced benefits.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/6a40bb1461bb0a67205c6bc8https://doi.org/10.1002/ccr3.73050
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes in refractory chronic graft-<i>versus</i>-host disease: the Italian multicenter experience with belumosudil2026
  2. 2Belumosudil for Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis2025
  3. 3Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study2026
  4. 4Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.2025
  5. 5Systemic Rho-kinase inhibitor belumosudil for treatment of ocular graft versus host disease2025 · 1 citations